Stockreport

A Second Anktiva Approval Could Be The Catalyst ImmunityBio Needs [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF IBRX's cash position improved to $257.8 million, providing a 3-4 quarter runway, though net debt remains high at $603 million. The company's robust adoption underpins [Read more]